Results 31 to 40 of about 82,696 (289)

The 6-minute walk test and other endpoints in Duchenne muscular dystrophy: longitudinal natural history observations over 48 weeks from a multicenter study. [PDF]

open access: yes, 2013
IntroductionDuchenne muscular dystrophy (DMD) subjects ≥5 years with nonsense mutations were followed for 48 weeks in a multicenter, randomized, double-blind, placebo-controlled trial of ataluren.
Abresch, R Ted   +12 more
core   +2 more sources

Is blood pressure reduction a valid surrogate endpoint for stroke prevention? an analysis incorporating a systematic review of randomised controlled trials, a by-trial weighted errors-in-variables regression, the surrogate threshold effect (STE) and the biomarker-surrogacy (BioSurrogate) evaluation schema (BSES)

open access: yesBMC Medical Research Methodology, 2012
Background Blood pressure is considered to be a leading example of a valid surrogate endpoint. The aims of this study were to (i) formally evaluate systolic and diastolic blood pressure reduction as a surrogate endpoint for stroke prevention and (ii ...
Lassere Marissa N   +3 more
doaj   +1 more source

An Integrated TCGA Pan-Cancer Clinical Data Resource to Drive High-Quality Survival Outcome Analytics [PDF]

open access: yes, 2018
For a decade, The Cancer Genome Atlas (TCGA) program collected clinicopathologic annotation data along with multi-platform molecular profiles of more than 11,000 human tumors across 33 different cancer types.
A. Abeshouse   +740 more
core   +2 more sources

Prognostic and therapeutic implications of measurable residual disease in acute myeloid leukemia

open access: yesJournal of Hematology & Oncology, 2021
Quantification of measurable residual disease (MRD) provides critical prognostic information in acute myeloid leukemia (AML). A variety of platforms exist for MRD detection, varying in their sensitivity and applicability to individual patients.
Marisa J. L. Aitken   +3 more
doaj   +1 more source

Metformin for non-diabetic patients with coronary heart disease (the CAMERA study): a randomised controlled trial [PDF]

open access: yes, 2009
<br>Background: Metformin reduces cardiovascular risk in patients with type 2 diabetes seemingly independent of lowering blood glucose concentration. We assessed the cardiovascular effects of metformin in individuals without type 2 diabetes.</br&
Eddy   +33 more
core   +5 more sources

What every ICU clinician needs to know about the cardiovascular effects caused by abdominal hypertension [PDF]

open access: yes, 2015
The effects of increased intra-abdominal pressure (IAP) on cardiovascular function are well recognized and include a combined negative effect on preload, afterload and contractility.
De Keulenaer, Bart L   +2 more
core   +1 more source

Bayesian meta-analytical methods to incorporate multiple surrogate endpoints in drug development process. [PDF]

open access: yes, 2015
A number of meta-analytical methods have been proposed that aim to evaluate surrogate endpoints. Bivariate meta-analytical methods can be used to predict the treatment effect for the final outcome from the treatment effect estimate measured on the ...
Abrams, KR   +3 more
core   +2 more sources

Applications of neuroimaging to disease-modification trials in Alzheimer's disease. [PDF]

open access: yes, 2009
Critical to development of new therapies for Alzheimer's disease (AD) is the ability to detect clinical or pathological change over time. Clinical outcome measures typically used in therapeutic trials have unfortunately proven to be relatively variable ...
Aisen, Paul S   +5 more
core   +2 more sources

What can we learn from SOCRATES: more questions than answers? [PDF]

open access: yes, 2017
This editorial refers to ‘Vericiguat in patients with worsening chronic heart failure and preserved ejection fraction: results of the SOluble guanylate Cyclase stimulatoR in heArT failurE patientS with PRESERVED EF (SOCRATES-PRESERVED) Study’, by B ...
Cleland, John G.F., Mueller, Christian
core   +1 more source

A modified weighted log-rank test for confirmatory trials with a high proportion of treatment switching [PDF]

open access: yes, 2020
In confirmatory cancer clinical trials, overall survival (OS) is normally a primary endpoint in the intention-to-treat (ITT) analysis under regulatory standards. After the tumor progresses, it is common that patients allocated to the control group switch
Bore, Alexander   +3 more
core   +2 more sources

Home - About - Disclaimer - Privacy